cbp-1008
coherent biopharma,ligand
['ovarian', 'cbp-1008 ', 'ligand']
dr. wu presents cbp-1008 a bispecific ligand drug conjugate targeting folate receptor &amp;trpv6 with a mmae backbone at #asco22 in s406: most common ae neutropenia. among ovarian dosed at least 0.15 mg/kg, orr 18.4%, if enriched fr expression and 1-3 priors, orr 40% 
Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine.